Provided by Tiger Fintech (Singapore) Pte. Ltd.

MSA Safety

134.16
-8.9000-6.22%
Post-market: 134.160.00000.00%16:05 EDT
Volume:296.53K
Turnover:40.23M
Market Cap:5.27B
PE:18.61
High:140.24
Open:139.09
Low:133.95
Close:143.06
Loading ...

MSA Safety Q4 Earnings, Revenue Rise

MT Newswires Live
·
13 Feb

MSA Safety sees 2025 revenue in low-single digits from 2024 revenue of $1.83B

TIPRANKS
·
13 Feb

MSA Safety Q4 Adj $2.25 Beats $2.24 Estimate, Sales $499.70M Miss $520.09M Estimate

Benzinga
·
13 Feb

MSA Safety reports Q4 adjusted EPS $2.25, consensus $2.26

TIPRANKS
·
13 Feb

MSA Safety Inc: Expecting Low-Single Digit Full-Year Organic Sales Growth in 2025

THOMSON REUTERS
·
13 Feb

BRIEF-MSA Safety Q4 Adjusted EPS USD 2.25 Vs. IBES Estimate USD 2.24

Reuters
·
13 Feb

MSA Safety Q4 EPS USD 2.22

THOMSON REUTERS
·
13 Feb

MSA Safety Announces Fourth Quarter and Full Year 2024 Results

PR Newswire
·
13 Feb

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

PR Newswire
·
12 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 Feb

Alterity Therapeutics Raises A$40.0 million in Placement

GlobeNewswire
·
10 Feb

Why MSA Safety Incorporated (NYSE:MSA) Could Be Worth Watching

Simply Wall St.
·
10 Feb

Health Check: Ansell gloves up for Trump tariff threat

Stockheads
·
10 Feb

MSA Safety Showcasing Automatic Leak Detection and Monitoring Expertise at AHR Expo

PR Newswire
·
07 Feb

The Hartford Unveils Refreshed Brand With Modernized Stag Logo

Business Wire
·
06 Feb

Health Check: Percheron ‘closes the book’ on failed childhood rare disease program

Stockheads
·
06 Feb

Theravance Biopharma to Participate in an Upcoming Investor Conference

PR Newswire
·
05 Feb

MSA Safety Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call

PR Newswire
·
04 Feb

MSA Safety (NYSE:MSA) Is Very Good At Capital Allocation

Simply Wall St.
·
31 Jan

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

GlobeNewswire
·
30 Jan